Announcement of cancellation of part of new
restricted employee shares by relevant authority
Date of events
2022/05/20
To which item it meets
paragraph 36
Statement
1.Date of the competent authority's approval of capital
reduction:2022/05/17
2.Date of completion of capitalization change registration:2022/05/17
3.Effect on the financial statements (including any
discrepancy between the amount of paid-in capital and
the no.of shares outstanding, and the effect on net
worth per share):
The cancellation of employee restricted shares was 65,000 shares, decreased
the share capital of NTD$650,000. After the cancellation of the employee
restricted shares, share capital is NT$1,631,328,250. The record date of the
employee restricted shares was April 22, 2022, there is no effect on the
2022Q1 consolidated financial statements.
4.Plan for expected exchange of shares:NA
5.Estimated no.of listed common shares after capital
reduction and new issue:NA
6.Estimated no.of listed
common shares as a percentage
of issued common shares after capital reduction and
new issue (No.of common
shares after capital reduction/No.of issued
common shares):NA
7.Countermeasures for poor circulation of equity if the
aforesaid estimated no.of
listed common shares does
not reach 5 million shares
and the percentage does not
reach 25% after capital
reduction:NA
8.Any other matters that need
to be specified:
ADDCN received the approval letter of the capital
amendment registration on May.20,2022.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Lumosa Therapeutics Co. Ltd. published this content on 20 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 May 2022 06:24:01 UTC.
LUMOSA THERAPEUTICS CO., LTD. is a Taiwan-based company principally engaged in the development of new drugs. The Company is engaged in the development of new drugs for unmet medical needs in the fields of central nervous system (CNS), oncology, and inflammatory diseases. The Company is engaged in scientific licensing and new drug development under the reSEARCH and DEVELOPMENT model.
LUMOSA THERAPEUTICS CO., LTD. 
